News

TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, announced the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab in women with recurrent…
Read More...

Evotec AG and The Global Antibiotic Research and Development Partnership are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of…
Read More...

Ono Pharmaceutical and twoXAR announced that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address…
Read More...

NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary oligonucleotide delivery technology to develop novel agents, announced that the company has entered into a…
Read More...

Novo Nordisk announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza (liraglutide).…
Read More...

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib…
Read More...

Xeris Pharmaceuticals announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes…
Read More...

Iktos announced a collaboration agreement with Merck KGaA, Darmstadt, Germany where Iktos generative modelling artificial intelligence (AI) technology will be used to facilitate the…
Read More...

Kitov Pharma announced it has signed an agreement to acquire FameWave Ltd., a privately held biopharmaceutical company developing CM-24, a clinical stage monoclonal antibody targeting…
Read More...

Patients with HER2-positive breast cancer face something of a predicament: The most effective drug to treat the cancer is also the most toxic. Trastuzumab, sold under the brand name…
Read More...

Roche announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition…
Read More...

Roche announced that the European Commission has approved Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII…
Read More...

CARB-X announced that it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early…
Read More...

Pharmaceutics International announced that the U.S. Food and Drug Administration (FDA) has issued their Establishment Inspection Reports (EIRs) for both FEI registration numbers…
Read More...

BioArctic AB (publ) announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805. The Phase 1 study in…
Read More...

Seres Therapeutics announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting…
Read More...

R&D alliance will enable ‘promising innovations to advance beyond their laboratory roots’ Harvard University and Deerfield Management, a health care investment firm, have…
Read More...

Hoth Therapeutics, a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as…
Read More...

Esperion announced that results from the 2,230 patient, 52-week, Phase 3 long-term safety study of bempedoic acid (CLEAR Harmony, also known as Study 1 or 1002-040) were published today…
Read More...

Agenus Inc. announced that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc. This milestone triggered a cash payment…
Read More...